Observational study finds 39% of GLP-1 users experience nail detachment issues — Evidence Review

A new multinational study has found that users of popular GLP-1 medications for weight loss and diabetes report nail detachment and other nail disorders at much higher rates than non-users. While prior research has focused on gastrointestinal side effects, this is the first controlled investigation to link GLP-1 drugs to specific nail and scalp issues; related studies generally agree on the prevalence of side effects but have not previously highlighted nail health concerns, as discussed in the original source.

• Most existing studies emphasize gastrointestinal side effects such as nausea, vomiting, and diarrhea as the primary adverse events associated with GLP-1 medications, with little attention to nail or scalp disorders 1 2 4 5.
• The new findings expand the known spectrum of possible side effects, suggesting that GLP-1 drugs may affect dermatological health in addition to the well-established gastrointestinal system, a concern not previously reported in systematic reviews or meta-analyses 2 4.
• While rapid weight loss alone has sometimes been linked to hair and nail changes, related dermatology research indicates that obesity itself does not substantially increase nail disorder risk, supporting the study's conclusion that weight loss does not fully explain these new observations 6.

Study Overview and Key Findings

GLP-1 receptor agonists have rapidly gained popularity for both obesity management and type 2 diabetes, but research on their long-term safety has mainly focused on metabolic and gastrointestinal effects. Reports of unusual nail and hair symptoms prompted researchers to conduct the first controlled study assessing the prevalence and characteristics of nail and scalp problems among GLP-1 users, aiming to clarify whether these issues are linked to the medications themselves or to weight loss and underlying health conditions. The study's multinational approach and large sample size provide a more comprehensive look at these potential side effects than prior case reports.

Property	Value
Study Year	2026
Organization	DUCRAY Laboratories (Pierre Fabre Group)
Authors	Dr. Charles Taïeb, Dr. Bruno Halioua
Population	People using GLP-1 medications for weight loss and diabetes
Sample Size	n=1904
Methods	Observational Study
Outcome	Nail and scalp health issues among GLP-1 users
Results	39% of GLP-1 users experienced nail detachment.

Key Findings

• Nail Disorders: Among GLP-1 users, 66% reported at least one nail disorder, with nail detachment (onycholysis) reported by 39% of users compared to 9% of non-users.
• Nail Discoloration: 46% of GLP-1 users reported nail discoloration versus 17% of controls.
• Hair and Scalp Changes: Hair loss was reported by 50% of GLP-1 users (vs 34% of non-users), with accompanying scalp symptoms such as redness and itching being more common in the user group.
• Role of Weight Loss: The increased prevalence of nail and scalp disorders among GLP-1 users was not fully explained by weight loss alone. Adjustments for pre-existing conditions and nutritional status reduced but did not eliminate the associations.
• Study Limitations: The cross-sectional design and reliance on self-reported symptoms limit causal inferences; prospective studies with clinical assessments are planned.

Literature Review: Related Studies

To understand the context of these findings, we searched the Consensus paper database, which contains over 200 million research papers. The following search queries were used to identify relevant studies:

1. GLP-1 weight loss drug side effects
2. nail detachment weight loss medications
3. fingernail issues obesity treatment drugs

Summary Table: Key Topics and Findings

Topic	Key Findings
What are the most common side effects of GLP-1 receptor agonists?	- Gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) are most frequently reported among both diabetic and non-diabetic users 1 2 4 5. - Serious but rare adverse events include pancreatitis and gallbladder disorders; dermatologic side effects were mentioned but not commonly highlighted 2 4.
Do GLP-1 medications lead to nail or dermatologic disorders?	- Dermatologic adverse events have been reported but are less common compared to gastrointestinal issues, and controlled studies on nail disorders have been lacking until now 2. - Obesity alone does not significantly increase the risk of nail psoriasis or nail disorders 6.
Are nail and hair changes primarily due to weight loss or medication effects?	- Rapid weight loss can affect nail and hair health, but studies in psoriasis suggest weight reduction alone does not increase nail disorder risk 6. - Related reviews have not identified nail or hair disorders as common side effects of GLP-1 therapy, suggesting a need for further investigation 1 4.
How do GLP-1 adverse effects differ between patient populations and indications?	- Non-diabetic and diabetic populations both experience higher rates of gastrointestinal adverse events with GLP-1 agonists, with some variation by specific drug 1 5. - No prior controlled studies have systematically evaluated dermatologic effects across diverse populations 2 4 5.

---

What are the most common side effects of GLP-1 receptor agonists?

The related literature consistently identifies gastrointestinal symptoms—such as nausea, vomiting, diarrhea, and constipation—as the most prevalent side effects for GLP-1 receptor agonists, regardless of whether they are used for weight loss or diabetes. Dermatologic issues, while occasionally reported, have not been systematically studied or highlighted in large meta-analyses or systematic reviews.

• Gastrointestinal symptoms are the leading side effects, often limiting tolerability and adherence to GLP-1 therapy 1 2 4 5.
• Serious adverse events, though rare, include pancreatitis and gallbladder disorders 2 4.
• Dermatologic side effects are mentioned in case reports but are not well characterized in controlled studies 2.
• The new study's focus on nail and scalp health represents a novel area of investigation, broadening the scope of known side effects for GLP-1 drugs.

Do GLP-1 medications lead to nail or dermatologic disorders?

Prior reviews and case reports have noted dermatological adverse events, but these are infrequent compared to gastrointestinal issues and are typically not the focus of systematic reviews. The relationship between GLP-1 use and nail disorders has not been established in previous controlled studies, making the new findings an important contribution.

• Dermatologic adverse effects, such as rashes or other skin changes, have been reported but are rare 2.
• Existing studies do not identify nail detachment or other nail disorders as a common adverse reaction to GLP-1 therapy 2 4.
• Research on obesity and nail health suggests that obesity itself does not significantly increase nail disorder risk 6.
• The current study provides new controlled data suggesting a higher prevalence of nail disorders among GLP-1 users, independent of obesity or weight loss 6.

Are nail and hair changes primarily due to weight loss or medication effects?

There is evidence that rapid weight changes can influence hair and nail health, but studies in conditions like psoriasis indicate that weight loss does not necessarily increase the risk of nail disorders. Most GLP-1 side effect studies have not reported nail or hair changes as prominent issues.

• Rapid weight loss can disrupt nutrition, potentially affecting nails and hair, but data from psoriasis studies suggest this is not a major factor in nail disease prevalence 6.
• Reviews of GLP-1 side effects focus primarily on gastrointestinal symptoms, with little mention of nail or hair disorders 1 4.
• The new study's finding that nail and scalp disorders remain more common in GLP-1 users even after accounting for weight loss suggests a possible medication effect.
• Further research is needed to clarify mechanisms and causality.

How do GLP-1 adverse effects differ between patient populations and indications?

Meta-analyses and systematic reviews confirm that both diabetic and non-diabetic populations experience increased rates of gastrointestinal side effects with GLP-1 agonists. However, the frequency and nature of less common adverse events, such as dermatologic issues, have not been well characterized or compared across groups.

• Both diabetic and non-diabetic patients report similar gastrointestinal side effect profiles, with possible variation by specific GLP-1 drug 1 5.
• Most studies have not systematically examined dermatologic outcomes in these populations 2 4 5.
• The current study's multinational sample provides new comparative data across diverse groups.
• Controlled longitudinal studies are needed to establish causality and clarify risk factors for less common adverse events.

Future Research Questions

The new findings underscore the need for further research into the dermatologic and trichologic (hair/scalp) effects of GLP-1 medications. Current knowledge is limited by a lack of prospective, controlled studies and an emphasis on self-reported symptoms. Addressing these gaps could help clarify causality, mechanisms, and best practices for monitoring and managing these side effects.

Research Question	Relevance
Are GLP-1 medications directly causing nail and scalp disorders?	Determining causality is crucial for understanding whether these symptoms are side effects of the drugs or related to other factors such as weight loss or underlying health conditions 2 4.
What are the mechanisms by which GLP-1 agonists might affect nail and hair health?	Identifying biological pathways could reveal why some users experience these symptoms and inform targeted prevention or treatment strategies 2 4.
Do nail and scalp disorders resolve after discontinuation of GLP-1 medications?	Understanding the reversibility and natural history of these symptoms will help guide clinicians and patients in management decisions 2.
Are certain GLP-1 drugs more likely to cause dermatologic side effects than others?	Drugs within the GLP-1 class may have different risk profiles; comparative studies could inform drug selection and minimize adverse effects 1 5.
What clinical monitoring should be implemented for patients on GLP-1 therapy to detect nail and scalp changes?	Establishing evidence-based monitoring recommendations could improve detection and management of these potential side effects in clinical practice 2 4.

---

This article summarizes the current state of research regarding GLP-1 medication side effects, particularly the newly identified dermatologic concerns, and highlights the need for further investigation to clarify causality, mechanisms, and optimal patient care.